Guyana vs Oman: Access to anti-retroviral drugs, male
Guyana
66.0%
in 2024
Oman
65.0%
in 2024
Guyana rank
80th
Oman rank
83rd
Access to anti-retroviral drugs, male over time
- Guyana
- Oman
How they compare
Guyana currently reports 66.0% against 65.0% in Oman, a difference of 1.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Oman ahead.
Guyana ranks 80th and Oman ranks 83rd of 141 countries.
Across the 3 decades both report, Guyana averaged higher in 2 and Oman in 1.
Head to head by decade
| Decade | Guyana | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 16.4% | 19.7% | 3.3% | Oman |
| 2010s | 49.2% | 33.4% | 15.8% | Guyana |
| 2020s | 60.8% | 58.4% | 2.4% | Guyana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Guyana or Oman?
- Guyana, at 66.0% against 65.0% in Oman as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Guyana and Oman?
- 1.0%, with Guyana ahead.
- How many years of comparable data are there for Guyana and Oman?
- 25 years are reported by both, from 2000 to 2024.
- How do Guyana and Oman rank globally for access to anti-retroviral drugs, male?
- Guyana ranks 80th and Oman ranks 83rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.